M&A / Deals BioAegis and Prenosis partner for inflammatory disease therapies pharminent April 22, 2026
M&A / Deals BioAegis and Prenosis partner for inflammatory disease therapies pharminent April 22, 2026
Policy / Pricing Medicare obesity drug pilot extended after insurer pushback pharminent April 22, 2026
Clinical Data BioAge says early data suggest ‘best-in-class’ potential for inflammation drug pharminent April 21, 2026
M&A / Deals Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs pharminent April 21, 2026
Clinical Data Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer pharminent April 21, 2026
Clinical Data AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data pharminent April 21, 2026
Clinical Data Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls pharminent April 21, 2026
Commercial The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground pharminent April 21, 2026
Pipeline Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine pharminent April 21, 2026
Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy pharminent April 21, 2026
Regulatory Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapy pharminent April 21, 2026
Clinical Data Nektar surges again as alopecia drug shows new promise in extension study pharminent April 20, 2026
M&A / Deals Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout pharminent April 20, 2026
Policy / Pricing FDA Achieves Year 1 Goals in Reducing Animal Testing in Drug Development pharminent April 20, 2026
Other AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle pharminent April 20, 2026
M&A / Deals Lilly adds gene delivery technology to CAR T in up to $7B Kelonia deal pharminent April 20, 2026
Clinical Data Novo’s late-stage sickle cell win piles pressure on competitors pharminent April 20, 2026
Other S16 Ep55: OncoBytes Adaptive Learning Pathways: Personalizing Treatment Plans to Optimize Adjuvant Therapy in Early-Stage HR+/HER2- Breast Cancer pharminent April 20, 2026
Market Access Beyond GLP-1Rs: emerging targets poised to gain share of obesity market pharminent April 20, 2026
Commercial The Omnichannel Gap: Building the CRM of the Future for Patient Services pharminent April 20, 2026